ArticleNature2017
Structural basis for selectivity and diversity in angiotensin II receptors.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 212 citations in OpenAlex.
- Article
- Molecular mechanisms for subtype selectivity of kinin receptors' antagonists.Nature communications · 2026Article
- The balance between classical and alternative renin-angiotensin system in ARDS: a narrative review.Journal of intensive care · 2026Review
- AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction.Addiction biology · 2026Review
- Viral mechanisms, tropism, and clinical relevance regarding the ophthalmic manifestations of SARS-CoV-2 infection.International journal of ophthalmology · 2026Review
- Advances in Crystallography and Cryo-Electron Microscopy for the Study of Membrane Proteins.Advances in experimental medicine and biology · 2026Review
- Systematic metabolite screening identifies functional regulators of the adenosine A2A receptor.Communications chemistry · 2025Article
- Expanding the Chemical Space of Mechanically Interlocked Peptides (MIPs) via Rational Design and Metabolite Profiling.JACS Au · 2025Article
- Vasoactive Agents in Burn Patients: Perspectives on Angiotensin-II.Journal of burn care & research : official publication of the American Burn Association · 2025Review
- Macromolecular crystallography and biology at the Linac Coherent Light Source.Journal of synchrotron radiation · 2025Article
- A perspective on small molecules targeting the renin-angiotensin-aldosterone system and their utility in cardiovascular diseases: exploring the structural insights for rational drug discovery and development.RSC medicinal chemistry · 2025Review
- Role of local angiotensin II signaling in bladder function.American journal of physiology. Renal physiology · 2024Review
- Innovative Strategies in X-ray Crystallography for Exploring Structural Dynamics and Reaction Mechanisms in Metabolic Disorders.Journal of personalized medicine · 2024Review
- The use of Guyton's approach to the control of cardiac output for clinical fluid management.Annals of intensive care · 2024Review
- G protein-coupled receptors and traditional Chinese medicine: new thinks for the development of traditional Chinese medicine.Chinese medicine · 2024Review
- G Protein-Coupled Receptor-Ligand Pose and Functional Class Prediction.International journal of molecular sciences · 2024Article
- Alternative Renin-Angiotensin System.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Gestational Intermittent Hypoxia Impairs ATJournal of biotechnology and biomedicine · 2024Article
- A rapid, tag-free way to purify functional GPCRs.The Journal of biological chemistry · 2024Article
- Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation.Current opinion in pharmacology · 2023Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 5 institutions in 2 countries.
Haitao ZhangDepartment of Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
Gye Won HanDepartment of Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
Alexander BatyukLinac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA.
Andrii IshchenkoDepartment of Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
Kate L WhiteDepartment of Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
Nilkanth PatelDepartment of Biological Sciences, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
Anastasiia SadybekovDepartment of Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
Beata ZamlynnyMRL, Merck &Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA.
Michael T RuddMRL, Merck &Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA.
Kaspar HollensteinMRL, Merck &Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA.
Alexandra TolstikovaCenter for Free Electron Laser Science, Deutsches Elektronen-Synchrotron DESY, Notkestraße 85, 22607 Hamburg, Germany.
Thomas A WhiteCenter for Free Electron Laser Science, Deutsches Elektronen-Synchrotron DESY, Notkestraße 85, 22607 Hamburg, Germany.
Mark S HunterLinac Coherent Light Source, SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA.
Uwe WeierstallDepartment of Physics, Arizona State University, Tempe, Arizona 85287, USA.
Wei LiuSchool of Molecular Sciences and Biodesign Center for Applied Structural Discovery, Biodesign Institute, Arizona State University, Tempe, Arizona 85287, USA.
Kerim BabaogluMRL, Merck &Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA.
Eric L MooreMRL, Merck &Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA.
Ryan D KatzMRL, Merck &Co., Inc., 503 Louise Lane, North Wales, Pennsylvania 19454, USA.
Jennifer M ShipmanMRL, Merck &Co., Inc., 503 Louise Lane, North Wales, Pennsylvania 19454, USA.
Margarita Garcia-CalvoMRL, Merck &Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA.
Sujata SharmaMRL, Merck &Co., Inc., 503 Louise Lane, North Wales, Pennsylvania 19454, USA.
Payal ShethMRL, Merck &Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA.
Stephen M SoissonMRL, Merck &Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA.
Raymond C StevensDepartment of Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
Vsevolod KatritchDepartment of Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
Vadim CherezovDepartment of Chemistry, Bridge Institute, University of Southern California, Los Angeles, California 90089, USA.
University of Southern California · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USArizona State University · USLinac Coherent Light Source · USUniversität Hamburg · DE
Funding
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6MProject 3U54GM094618 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI STEVENS, RAYMOND C · 2010 to 2014
$17.1MHT structure determination of GPCRs by LCP serial femtosecond nanocrystallographyR01GM108635 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEREZOV, VADIM · 2014 to 2017
$1.5MNIGMS NIH HHS P41 GM103393NIGMS NIH HHS R01 GM108635NIGMS NIH HHS U54 GM094618
Abstract
The angiotensin II receptors AT
Indexed as
Models, MolecularAngiotensin II Type 2 Receptor Blockersbeta-ArrestinsBinding SitesCrystallography, X-RayDrug DesignHeterotrimeric GTP-Binding ProteinsHumansLigandsMolecular Docking SimulationMutationProtein BindingProtein ConformationReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Signal TransductionAngiotensin II Type 2 Receptor Blockersbeta-ArrestinsHeterotrimeric GTP-Binding ProteinsLigandsReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.